Fractyl Health Eyes 2028 Revita Launch for Post-GLP-1 Weight Maintenance

Key Points

• Fractyl Health is targeting a potential early-2028 U.S. launch for its investigational Revita endoscopic procedure, designed to help patients maintain GLP-1-related weight loss after discontinuing medication. The company expects six-month REMAIN-1 data in early Q4 2026 and plans a possible FDA De Novo submission in late 2026.
• Midpoint trial results showed patients receiving complete duodenal ablation retained up to 84% of their GLP-1-induced weight loss after one year, versus 46% for sham-treated patients. Fractyl reported no device-related serious adverse events through 12 months, though FDA authorization is not assured.
• The company plans to launch through 30–50 established metabolic and bariatric centers initially, expanding to as many as 200. Management estimates a $10,000–$30,000 procedure price, 5,000–10,000 annual procedures in 2029 and potential cash profitability that year, contingent on clinical, regulatory and reimbursement success.

Fractyl Health NASDAQ: GUTS outlined a commercial strategy for its investigational Revita procedure, positioning the one-time endoscopic therapy as a potential option for patients seeking to maintain weight loss after discontinuing GLP-1 medicines.

The company said Revita is designed for post-GLP-1 weight maintenance and remains investigational in the United States. Fractyl plans to pursue a potential FDA De Novo marketing application in late 2026 if results from its REMAIN-1 pivotal study are favorable. Management said it expects topline six-month data from the more than 300-patient pivotal cohort in early fourth-quarter 2026, followed by one-year data in the first quarter of 2027.

Focus on Weight Maintenance After GLP-1 Discontinuation

Co-Founder and CEO Harith Rajagopalan said the central unmet need in obesity treatment has shifted from achieving weight loss to maintaining it after patients stop GLP-1 drugs. He cited an estimated 29 million U.S. patients currently using GLP-1 medicines for weight loss and said more than 1 million discontinue treatment each month, often because of cost, side effects or access issues.

Rajagopalan said there is currently no FDA-approved therapy specifically intended to help patients maintain GLP-1-related weight loss after stopping medication. He described Revita as an outpatient endoscopic procedure that treats the duodenal mucosa without resection, implants, suturing or permanent anatomical changes.

“It is designed to complement lifestyle changes and pharmacology, not replace them,” Rajagopalan said.

In the company’s open-label REVEAL-1 cohort of 22 patients, participants retained about 78% of the total body weight loss achieved while taking a GLP-1 drug one year after receiving Revita, according to the company. In the randomized REMAIN-1 midpoint cohort, Fractyl reported that patients receiving complete duodenal ablations retained up to 84% of GLP-1-induced weight loss at one year, compared with 46% for sham-treated patients.

Fractyl said the midpoint study recorded no device-related serious adverse events through 12 months. All four related events were Grade 1, occurred on the procedure day and were transient, according to the company.

Regulatory and Center-of-Excellence Plans

Fractyl said it received favorable FDA pre-submission feedback in March, with the agency indicating that Revita’s safety profile was consistent with a potential Class II De Novo device classification. The company cautioned that the feedback was advisory and non-binding, and that FDA authorization is not assured.

Mike Zumdahl, Fractyl’s senior vice president of market access and commercial strategy, said the company intends to launch through established metabolic and bariatric centers rather than build a broad new provider network. Fractyl identified roughly 1,000 accredited U.S. centers of excellence and said it would initially focus on approximately 100 to 200 centers.

The first phase of a potential launch would target 30 to 50 high-readiness centers during 2028, followed by expansion to 60 to 90 centers in 2029 and 100 to 200 centers thereafter. The company’s early targets include REMAIN-1 clinical sites and centers where it already has physician relationships.

Zumdahl said Fractyl views bariatric surgeons with endoscopic capabilities and gastrointestinal endoscopists with metabolic practices as its primary customers. The company estimates its addressable operator pool includes 300 to 400 GI endoscopists with active bariatric practices and 2,000 to 3,000 bariatric surgeons.

Dr. Folahan Ayoola, medical director of bariatric surgery at Texas Health, said GLP-1 therapies have materially changed bariatric practice patterns. Ayoola said his surgical volume declined from more than 300 annual cases to more than 150 as GLP-1 medications became more widely used, while his clinic now manages approximately 2,000 patients receiving GLP-1 treatments.

Ayoola said patients frequently want to avoid lifelong medication use and are interested in a non-surgical approach that does not permanently alter anatomy. He said his facility could potentially perform 400 to 500 such procedures annually if Revita is approved, given its existing endoscopy, fluoroscopy and clinical infrastructure.

Coverage, Pricing and Profitability Assumptions

Fractyl filed an application for a Category III CPT code in June and anticipates that the code could become effective in 2027. The company said it is also pursuing Medicare coverage pathways tied to Revita’s breakthrough device designation, including potential transitional pass-through payment for hospital facilities.

Management said its early financial model assumes most initial patients would come through CMS-related coverage, while private-payer reimbursement could build over time. The company plans to use a prospective registry to collect longer-term real-world evidence for payer discussions.

Fractyl estimated an annual U.S. addressable market of $40 billion to $120 billion, based on an estimated 4 million eligible post-GLP-1 patients per year and an assumed procedure price of $10,000 to $30,000. Management did not disclose a planned commercial price, but CFO Lara Smith Weber cited a reimbursement benchmark range of roughly $11,000 to $33,000 based on existing endoscopic and bariatric procedures.

The company expects a potential U.S. launch in early 2028, subject to FDA authorization and payment arrangements. It projected 5,000 to 10,000 annual procedures in 2029 and said potential cash profitability could occur that year, or approximately five to eight quarters after launch. Fractyl emphasized that these projections are management estimates, not guidance, and depend on favorable pivotal data, FDA authorization, coverage and financing.

About Fractyl Health (NASDAQ:GUTS)

Fractyl Health, Inc is a clinical-stage medical technology company focused on the development and commercialization of minimally invasive, endoscopic therapies for metabolic diseases. Headquartered in Lexington, Massachusetts, Fractyl is advancing treatments that target the underlying physiology of conditions such as type 2 diabetes, obesity and nonalcoholic fatty liver disease (NAFLD) by modifying the duodenal mucosa to improve metabolic control.

The company's lead product, Revita® Duodenal Mucosal Resurfacing (Revita DMR), employs a catheter-based hydrothermal ablation technique to remodel the lining of the upper small intestine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source